The stock of Guardion Health Sciences Inc (GHSI) closed the recent trading session at $0.28, gaining 47.84% from the previous session. During the last check, the stock of GHSI remained bullish in the pre-market, gaining 49.29% to $0.418. GHSI declared the closing of its preceding public offer. The company also filed for the form SC 13G with SEC on 28 February 2022.
Guardion Health Sciences Inc (GHSI) is a clinical nourishment and diagnostics organization. GHSI creates clinical food varieties and clinical gadgets in the visual wellbeing space and creates nutraceutical items to give steady medical advantages to clients. The organization’s clinical gadgets are utilized to quantify visual capacity and certain physical elements of the eye that recognize early sickness. The firm has a market cap of $6.83mn and 24.43mn shares pending. The firm has its headquarter in Houston, Texas, United States of America (USA).
GHSI’s News
On 23 February 2022, Guardion Inc declared the closing of its preceding public offering of 37 million stocks. GHSI issued warrants A and warrants B to buy up to 37 million of the normal stock. The price of the normal stock was $0.30 per stock. Further, warrant A had the price of $0.37 per stock with validity for five years from the issue date. While the warrant B had the price of $0.37 with a validity for 18 months from the issue date. Moreover, the total amount from the public offering was $11 million.
On February 14, 2022, GHSI reported about the release of its Viactiv Omega Boost gel bites. The Omega gel bites are intended to give all out the body support, including cardiovascular, neurological, joint, and visual wellbeing. The CEO of GHSI, Bret Scholtes, stated that they are eager to have the option to offer steady supplements under the reliable Viactiv brand. He further added that they anticipate being a dependable asset for the nourishing enhancement needs of their clients.
